¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primaquine phosphate sensitivity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • physics depth sensitivity
    ¹°¸®Àû±íÀ̹ਵµ
  • spectral sensitivity
    ºÐ±¤¹Î°¨µµ
  • sensitivity
    1. °¨¼ö¼º 2. ¹Î°¨µµ
  • sensitivity control
    °¨µµÁ¶Á¤±â, °¨µµÁ¶Àý
  • sensitivity current
    °¨µµÀü·ù
  • sensitivity test
    ¹Î°¨µµ°Ë»ç
  • short increment sensitivity index test
    ¹Ì¼¼Áõ°¡°¨¼ö¼ºÁö¼ö°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • oxytocin sensitivity test
    ¿Á½ÃÅä½Å¹Î°¨µµ°Ë»ç
  • physics depth sensitivity
    ¹°¸®Àû±íÀ̹ਵµ
  • radiation sensitivity test
    ¹æ»ç¼±¹Î°¨µµ°Ë»ç
  • sensitivity
    ¹Î°¨µµ
  • sensitivity test
    ¹Î°¨µµ½ÃÇè
  • short increment sensitivity index test
    ¹Ì¼¼Áõ°¡°¨¼ºÁö¼ö°Ë»ç
  • spectral sensitivity
    ºÐ±¤¹Î°¨µµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Glycerol 3-phosphate
    ±Û¸®¼¼·Ñ-3-Àλê(×òß«)
  • High energy phosphate
    °í¿¡³ÊÁöÀλê
  • Sorensens phosphate buffer
    ¼î·»¼¾Àλê¿ÏÃæ¾×
  • ammonium magnesium phosphate crystal
    Àλê¾Ï¸ð´½¸¶±×³×½·°áÁ¤
  • fructose-1-phosphate aldolase
    ÇÁ¶ôÅ佺-1-Æ÷½ºÆäÀÌÆ®¾Ëµ¹¶óÁ¦
  • galactose-1-phosphate uridyl tranferase
    °¥¶ôÅ佺-1-Æ÷½ºÆäÀÌÆ®¿ì¸®µôÀüÀÌÈ¿¼Ò
  • glactose-1-phosphate uridyl transferase
    Glactose-1-phosphate uridyl transferase
  • glucose 6 phosphate
    ±Û·çÄÚ¿À½º-6-Àλê.
  • glucose 6 phosphate dehydrogenase =G 6 PD
    ±Û·çÄÚ¿À½º 6Àλê Å»¼ö ¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½º-6-ÀÎ»ê µ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose 6 phosphate dehydrogenase def
    ±Û·çÄÚ¿À½º-6-Àλê Å»¼ö¼Ò È¿¼Ò°á
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ¿À½º-6-ÀλêÅ»¼ö¼ÒÈ¿¼Ò
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀ̵å·ÎÀú³×À̽º
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glycerol phosphate
    Àλê±Û¸®¼¼·Ñ.
  • guaiacol phosphate
    Àλê(ìÝß«)°úÀ̾îÄÝ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • optimal sensitivity
    ÃÖÀû°¨µµ(õÌîêÊïöô).
  • optimum sensitivity
    ÃÖÀû°¨µµ(õÌîêÊïöô).
  • optochin disc sensitivity test
    ¿ÉÅäŲ ¿øÆÇ°¨¼ö¼º½ÃÇè (Æó·Å±¸±Õ µ¿Á¤¿ë)
  • optochin sensitivity
    ¿ÉÅäŲ °¨¼ö¼º°Ë»ç (Æó·Å±¸±Õ µ¿Á¤¿ë)
  • oxytocin sensitivity test =OST
    ¿Á½ÃÅä½Å °¨¼ö¼º °Ë»ç.
  • oxytocin sensitivity test =OST
    ¿Á½ÃÅä½Å °¨¼ö¼º Å×½ºÆ®.
  • physics depth sensitivity
    ¹°¸®Àû ±íÀÌ ¿¹¹Îµµ
  • radiation sensitivity
    ¹æ»ç¼±°¨¼ö¼º
  • radiation sensitivity test, RST
    ¹æ»ç¼±°¨¼ö¼º°Ë»ç
  • receptor sensitivity
    ¼ö¿ëü °¨¼ö¼º
  • sensitivity
    °¨µµ
  • sensitivity
    1. ¹Î°¨¼º(ÀϹÝÀû »ç¿ë), 2. ¹Î°¨µµ(Åë°è)
  • sensitivity analysis
  • sensitivity control
    °¨µµÁ¶Á¤±â, °¨µµÁ¶Àý.
  • sensitivity current
    °¨µµÀü·ù(Êïöôï³êü).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inorganic phosphate
    ¹«±âÀλê(ÙíѦ×òß«)
  • labile phosphate group
    ºÒ¾ÈÁ¤Àλê±â(ÝÕäÌïÒ×ò߫Ѩ)
  • nicotinamide adenine dinucleotide phosphate
    ", ´ÏÄڴѾƸ¶ÀÌµå ¾Æµ¥´Ñ ÀÌ(ì£) ´©Å¬·¹¿ÀŸÀ̵å Àλê(×òß«)"
  • p-nitrophenyl phosphate
    p-³ªÀÌÆ®·ÎÆä´Ò Àλê(×òß«)
  • pyridoxal phosphate
    ÇǸ®µ¶»ì Àλê(×òß«)
  • pentose phosphate carboxylase
    Àλê(×òß«)ÆæÅ佺 Ä«¸£º¹½Ç·¹À̽º
  • pentose phosphate pathway
    Àλê(×òß«ÆæÅ佺 °æ·Î(ÌèÖØ)
  • phosphate
    Àλ꿰(×òß«ç¤)
  • phosphate acceptor peptide
    Àλê¼ö¿ë(×òß«áôé») ÆéŸÀ̵å
  • phosphate bond energy
    Àλê°áÇÕ(×ò߫̿ùê) ¿¡³ÊÁö
  • phosphate group
    Àλê±â(×òß«Ðñ)
  • phosphate group transfer
    Àλê±â ÀüÀÌ(×òß«Ðñï®ì¹)
  • phosphate potential
    Àλê ÀüÀ§(×òß«ï³êÈ)
  • phosphate regulon
    Àλê(×òß«)·¹±¼·Ð (ÔÒ) phoÁ¶ÀýÀ¯ÀüÀÚ(ðàï½ë¶îîí­)
  • phosphate transfer potential
    ÀλêÀüÀÌ ÀüÀ§(×òß«ï®ì¹ï³êÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GPD glucose-6-phosphate dehydrogenase; glycerol-phosphate dehydrogenase
PD Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p...
PPP pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p...
TCP T-complex protein; therapeutic continuous penicillin; total circulating protein; transcutaneous pace...
ISI International Sensitivity Index of reagent/instrument combination
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AS Anxiety sensitivity
BRS Baroreceptor reflex sensitivity
BRS Baroreflex sensitivity
BS Baroreflex sensitivity
CSF Contrast Sensitivity Function
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sensitivity test
    °¨µµ °Ë»ç, °¨µµ ½ÃÇè, °¨¼ö ½ÃÇè, °¨¼ö¼º ½ÃÇè, °¨¼ö¼º °Ë»ç
    ±ÕÀÇ È­ÇÐ ¿ä¹ýÁ¦¿¡ ´ëÇÑ °¨¼ö¼ºÀ» Á¶»çÇÏ¿© ±× °á°ú¿¡ À¯È¿ÇÑ ¾àÁ¦¸¦ ¼±ÅÃÇϱâ À§ÇØ ½Ç½ÃÇÏ´Â °Ë»ç.
  • sensitivity to touch of the scalp
    µÎÇÇ Á¢ÃË ½ÃÀÇ °ú¹Î¼º
  • spectral sensitivity
    ºÐ±¤ °¨µµ, ½ºÆåÆ®·³ ¹Î°¨µµ
  • alkaline phosphate
    ¾ËÄ®¸®¼º Àλ꿰
  • calcium phosphate
    Àλê Ä®½·
    Ä®½·±â¿Í ÀÎ»ê ±â¸¦ °¡Áø ¿°À¸·Î ¼¼ °¡Áö ÇüŰ¡ ÀÖ´Ù.
  • dicalcium phosphate
    Àλê Ä®½·
  • exsiccated sodium phosphate
    °ÇÁ¶ ÀÎ»ê ³ªÆ®·ý
  • high energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÎ»ê °áÇÕ ÇüŰ¡ ³ôÀº ¿¡³ÊÁö·Î ÀÌ·ç¾îÁø »óÅÂ. ÀÌ °áÇÕÀº ¾Æ³×³ë½Å »ïÀλê. Æ÷½ºÆ÷Å©·¹¾ÆÆ¾. ´ç ´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high-energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÌ °áÇÕÀº ¾Æµ¥³ë½Å »ïÀλê, Æ÷½ºÆ÷Å©·¹¾ÆÆ¾, ´ç´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • magnesium ammonium phosphate
    ¾Ï¸ð´½ ÀÎ»ê ¸¶±×³×½·
  • magnesium phosphate
    ÀÎ»ê ¸¶±×³×½·
    ºÎÇǰ¡ ¸¹Àº Èò»ö ºÐ¸».
  • oleandomycin phosphate
    ÀÎ»ê ¿Ã·¹¾Èµµ¸¶À̽Å
    ÁÖ·Î Æ÷µµ»ó ±¸±Õ ¹× ´Ù¸¥ Àü½Å¼º Ç×»ý ¹°Áú¿¡ ÀúÇ×ÀÌ ÀÖ´Â ±×¶÷ ¾ç¼º ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°ÀÇ Ä¡·á¿¡ »ç¿ëµÇ¸ç, ºñ°æ±¸ÀûÀ¸·Î »ç¿ëµÈ´Ù. ÀÛ¿ë ¹× ¿ëµµ°¡ ¿¡¸®Æ®·Î¸¶À̽Űú Èí»çÇϳª Ç×±Õ ÀÛ¿ëÀÌ ¾àÇÏ´Ù.
  • phosphate
    ÀÎ, Àλ꿰
  • phosphate buffered saline
    Àλ꿰 ½Ä¿°¼ö
  • phosphate depletion
    Àλ꿰 °í°¥
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
clinical sensitivity Test positivity in disease; ability of a test to correctly identify disease.
See: diagnostic sensitivity.
(05 Mar 2000)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
mumps sensitivity test A skin test for sensitivity to mumps, in which inactivated mumps virus is used as antigen.
(05 Mar 2000)
contact sensitivity Allergic response to contact with irritant, usually a hypersensitivity.
(18 Nov 1997)
contrast sensitivity The ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours. Psychophysical measurements of this visual function are used to evaluate visual acuity and to detect eye disease.
(12 Dec 1998)
salt sensitivity The tendency of certain bacterial suspensions to agglutinate spontaneously in physiological saline solution.
(05 Mar 2000)
sensitivity <microscopy> Similar to responsively of an image pickup tube but numerically different. The signal current developed in an image pickup tube per unit incident radiation density (watt per unit area) or illuminance (lux on the faceplate). Unless otherwise specified, the radiation is understood to be that of an unfiltered incandescent source at 2854 or 2856[[macron]]K.
(05 Aug 1998)
sensitivity and specificity Measures for assessing the results of diagnostic and screening tests. Sensitivity represents the proportion of truly diseased persons in a screened population who are identified as being diseased by the test. It is a measure of the probability of correctly diagnosing a condition. Specificity is the proportion of truly nondiseased persons who are so identified by the screening test. It is a measure of the probability of correctly identifying a nondiseased person.
(12 Dec 1998)
sensitivity training group A group in which members seek to develop self-awareness and an understanding of group processes rather than to obtain therapy for an emotional disturbance.
See: encounter group, personal growth laboratory.
(05 Mar 2000)
sensitivity training groups A group of people who meet in an unstructured setting to learn about themselves, interpersonal relationships, and group processes and about larger social systems.
(12 Dec 1998)
small increment sensitivity index The sounding of a tone 20 dB above threshold, followed by a series of 200-msec tones 1 dB louder; perception of these is indicative of cochlear damage.
Synonym: small increment sensitivity index test.
(05 Mar 2000)
small increment sensitivity index test The sounding of a tone 20 dB above threshold, followed by a series of 200-msec tones 1 dB louder; perception of these is indicative of cochlear damage.
Synonym: small increment sensitivity index test.
(05 Mar 2000)
spectral sensitivity The reciprocal of the amount of monochromatic radiation that produces a fixed response.
(05 Mar 2000)
diagnostic sensitivity The probability (P) that, given the presence of disease (D), an abnormal test result (T) indicates the presence of disease; i.e., P(T/D).
See: clinical sensitivity.
(05 Mar 2000)
disk sensitivity method A procedure for testing the relative effectiveness of various antibiotics; small disks of paper (or other suitable material) are impregnated with known, appropriate amounts of antibiotic, and then placed on the surface of semisolid medium that has been previously inoculated with the organism being tested; after suitable periods of incubation at 37°C, the lack of growth in zones about the various disks indicates the relative effectiveness of the antibiotic.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á